Human leukocyte antigen-DR presenting Tetanus Toxin 830-844 epitope (HLA-DR/TT830-844)

Human leukocyte antigen-DR (HLA-DR) molecules presenting the Tetanus Toxin 830-844 (TT830-844) epitope represent a specific peptide-major histocompatibility complex (pMHC) class II assembly. The TT830-844 peptide (sequence: QYIKANSKFIGITEL) is a well-characterized 'universal' or 'promiscuous' T-cell epitope, meaning it can bind to a wide variety of HLA-DR alleles across diverse human populations (Panina-Bordignon et al., 1989, Eur J Immunol). Its primary biological function is to be displayed on the surface of antigen-presenting cells (APCs) for recognition by the T-cell receptors (TCRs) of CD4+ T helper cells, which triggers T-cell activation and the subsequent orchestration of the adaptive immune response (UniProt P01903). In clinical medicine, this complex is a critical target in the development of peptide-based vaccines and immunotherapies, where the TT830-844 peptide is often used as a 'helper' epitope to enhance the immunogenicity of other antigens, such as those in cancer vaccines like SurVaxM (ClinicalTrials.gov, NCT02452424). By leveraging pre-existing memory T cells from prior tetanus vaccinations, drugs targeting this complex can significantly boost therapeutic efficacy. Safety considerations include potential hypersensitivity or systemic immune activation due to the high prevalence of anti-tetanus immunity in the general population.

Other names

HLA-DR/TT830-844 complexMHC class II/TT830-844Tetanus toxin peptide 830-844/HLA-DR complexUniversal T-helper epitope TT830-844/MHC II complex

The complex acts as a ligand for T-cell receptors (TCRs) on CD4+ T helper cells, initiating an intracellular signaling cascade that leads to T-cell activation and cytokine production.